IL-31 monoclonal antibodies and methods of use

摘要

There is provided a monoclonal antibody wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from a first group consisting of: a) ATCC Patent Deposit Designation PTA-6815; b) ATCC Patent Deposit Designation PTA-6816; c) ATCC Patent Deposit Designation PTA-6871; d) ATCC Patent Deposit Designation PTA-6829; and e) ATCC Patent Deposit Designation PTA-6830; or wherein the monoclonal antibody is selected from a second group consisting of: a) ATCC Patent Deposit Designation PTA-6831; b) ATCC Patent Deposit Designation PTA-6872; c) ATCC Patent Deposit Designation PTA-6875; and d) ATCC Patent Deposit Designation PTA-6873; for use in treating a disease selected from the group consisting of prurigo nodularis; cutaneous T cell lymphoma; atopic dermatitis; contact dermatitis; drug-induced allergic reactions; skin-tropic viruses; viral associated pruritis; vitiligo; alopecia aerata; acne rosacea; acne vulgaris; and bullous pemphigoid.